GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

Several other brokerages also recently issued reports on GOVX. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Noble Financial raised their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. Finally, Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.25.

GeoVax Labs Trading Down 6.9 %

Shares of GOVX traded down $0.18 during mid-day trading on Friday, reaching $2.43. The company had a trading volume of 859,139 shares, compared to its average volume of 2,512,010. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18. The company’s 50-day moving average is $2.37 and its 200-day moving average is $2.60.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same quarter last year, the company earned ($4.80) earnings per share. On average, sell-side analysts predict that GeoVax Labs will post -5.1 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.